comparemela.com

Latest Breaking News On - Medical oncology - Page 3 : comparemela.com

Pfizer's LORBRENA Study: Majority ALK+ Lung Cancer Patients Live Five Years Disease-Free

Pfizer's LORBRENA Study: Majority ALK+ Lung Cancer Patients Live Five Years Disease-Free
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

South-korea
China
Australia
Japan
Canada
United-states
American
Kenneth-culver
Roger-dansey
Department-of-medical-oncology
European-union
Peter-maccallum-cancer-centre

Dr Kalinsky on Abemaciclib/Fulvestrant in HR+/HER2– Breast Cancer Post–CDK4/6i Progression

Kevin Kalinsky, MD, MS, on abemaciclib plus fulvestrant in HR-positive/HER2-negative advanced breast cancer after progression on a CDK4/6 inhibitor and endocrine therapy.

Kevin-kalinsky
Glenn-family-breast-center
Division-of-medical-oncology
Breast-cancer-research
Department-of-hematology
Winship-cancer-institute-of-emory-university
Emory-university-school-of-medicine
Medical-oncology
Emory-university-school
Rand-glenn-family-chair
Breast-medical-oncology
Winship-cancer-institute

DFS, OS Benefit Maintained With Adjuvant Atezolizumab vs BSC in Stage II/IIIA NSCLC

Long-term DFS and OS outcomes with adjuvant atezolizumab in stage II to IIIA NSCLC were consistent with prior data from the IMpower010 trial.

Winston-chen
Heathera-wakelee
Stanford-cancer-institute
Phyllis-huang-professor
Stanford-medicine
Medical-oncology

ASCO 2024: Zanzalintinib (XL092) plus Nivolumab in Non-Clear Cell Renal Cell Carcinoma: The Randomized Phase 3 STELLAR-304 Study

ASCO 2024 phase III STELLAR-304 trial, combination of zanzalintinib (XL092) plus nivolumab in patients with non-clear cell renal cell carcinoma (nccRCC), tyrosine kinase inhibitor (TKI) sunitinib.

Toronto
Ontario
Canada
United-states
Chicago
Illinois
American
America
Sumantak-pal
Sumanta-pal
American-society-of-clinical-oncology
Twitter

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company…

China
Tongji
Sichuan
Suzhou
Jiangsu
Rhui-zhou
Guangdong
United-states
Hong-kong
Shanghai
Taiwan
Macau

vimarsana © 2020. All Rights Reserved.